Agilent Technologies, Inc. (A) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended January 31, 2026. Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied markets, providing instruments, software, services, and consumables. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Net Revenue | $1,798 | $1,681 |
| Income from Operations | $353 | $376 |
| Net Income | $305 | $318 |
| Diluted EPS | $1.07 | $1.11 |
| Operating Margin | 19.7% | 22.4% |
| Gross Margin | 52.6% | 53.5% |
| Operating Cash Flow | $268 | $431 |
| Cash and Equivalents (End of Period) | $1,758 | $1,470 |
| Total Debt (Short + Long Term) | $3,354 | $3,354 |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 7% year-over-year, driven by growth across all segments and geographic regions. Foreign currency movements provided a 3 percentage point favorable impact.
- Margin Compression: Operating margin decreased 3 percentage points to 19.7%. This was primarily due to higher tariffs, increased corporate infrastructure expenses, restructuring costs ($20 million), and transformational initiative expenses.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 16% to $476 million, attributed to restructuring, transformation initiatives, and wage increases. R&D expenses increased 4% to $117 million.
- Cash Flow: Operating cash flow decreased significantly to $268 million from $431 million, largely due to higher payments for variable/incentive pay ($150 million vs. $98 million) and income taxes ($105 million vs. $19 million).
- Segment Performance:
- Life Sciences & Diagnostics: Revenue +5%, Operating Income -7%.
- Agilent CrossLab: Revenue +9%, Operating Income +8%.
- Applied Markets: Revenue +7%, Operating Income +10%.
Guidance, Outlook, and Risks
- Tariff Impact: Management expects to fully offset the adverse impact of tariffs on costs of revenue during fiscal year 2026 through supply chain optimization and pricing actions. However, judicial rulings on tariff legality create ongoing uncertainty.
- Restructuring: The FY25 restructuring plan is expected to result in $90–$95 million in annual cost savings. Approximately $20 million in expenses were recorded in Q1 2026, with activities expected to be substantially complete by the end of fiscal 2026.
- Capital Allocation: The company repurchased 1.05 million shares for $152 million under the 2024 program, with approximately $1.8 billion remaining authorized. A quarterly dividend of $0.255 per share was declared.
- Market Outlook: Management remains optimistic about long-term end market health, noting that customer capital spending is normalizing, though U.S. federal government-funded customers remain constrained.
- Risks: Key risks include global economic conditions, foreign currency fluctuations, supply chain disruptions, and the potential for further trade policy changes or tariffs.
Investor Verification Checklist
- Tariff Mitigation: Verify the specific pricing actions and supply chain shifts implemented to offset the stated tariff impacts on gross margin.
- Restructuring Savings: Monitor the realization of the projected $90–$95 million in annual cost savings from the FY25 plan in subsequent quarters.
- Government Funding: Assess the extent of revenue exposure to U.S. federal government funding and the potential impact of budgetary constraints or shutdowns.
- Working Capital: Review the trend in Days Sales Outstanding (DSO), which increased to 76 days from 71 days, and inventory days on hand (112 days).
- CDMO Margins: Investigate the specific drivers behind the lower gross margin in the specialty Contract Development and Manufacturing Organization (CDMO) business mentioned in the Life Sciences segment.